NCT06605365已完成不适用
Ophthalmic Solution in Drye Eye Patients
D&V FARMA srl1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2021年9月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- TBUT
研究概览
简要总结
Data analyses and revision of the DED symptoms. A novel ophthalmic solution containing cross-linked CMC (CX-CMC) and Silk Proteins (SP) has been made available on the market.
Both molecules have been widely studied for their viscoelastic and hydrating, and wound healing properties.
This new ophthalmic solution is the first on the market formulated with a CX-CMC and SP.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects affected by dry eye disease
排除标准
- •know allergies to CX-CMC
- •know allergies to SP
结局指标
主要结局
TBUT
时间窗: 3 months
Tear Breakup Time
次要结局
- OSDI(3 months)
- Wound Healing(30 hours)
- UV and Blue light absorption(0 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Cross-linked Hyaluronic Acid and Coenzyme Q10 in the Treatment of Dry EyeDry Eye SyndromeNCT03074344Azienda Ospedaliera Universitaria Policlinico "G. Martino"40
已完成
4 期
The DEPOT Study (Dry Eye Prescription Options for Therapy)Dry EyeNCT04911361Research Insight LLC50
已完成
不适用
Clinical Research of Diquas ophthalmic solution 3% on corneal epithelial barrier function in dry eyeDry eyeJPRN-UMIN000021884Collaborative joint clinical research organized with Kyorin university School of Medicine and Santen Pharmaceutical Co., Ltd.20
已完成
2 期
Safety and Efficacy of an Ophthalmic Solution in Dry Eye DiseaseDry Eye DiseaseNCT00758784Bausch & Lomb Incorporated38
已完成
2 期
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye DiseaseDry Eye DiseaseNCT00667004Bausch & Lomb Incorporated183